# Xilio Therapeutics, Inc.: overview

XLO · Nasdaq · CIK 1840233 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xlo.md) · [Financials](/companies/xlo/financials.md) · [Filings](/companies/xlo/filings.md) · [Insiders](/companies/xlo/insiders.md)

Latest reported revenue: [$18.7m](/filings/0001193125-26-345759.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-345759).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.3](/filings/0001193125-25-278837.md) | [1.7 d](/filings/0001193125-26-118550.md) | [2.9](/filings/0001193125-26-218200.md) | [8.1](/filings/0001193125-26-345759.md) | [19.1](/filings/0001193125-25-278837.md) | [13.7 d](/filings/0001193125-26-118550.md) | [12.6](/filings/0001193125-26-218200.md) | [18.7](/filings/0001193125-26-345759.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(652.3%)](/filings/0001193125-25-278837.md) | [(790.5%) d](/filings/0001193125-26-118550.md) | [(472.7%)](/filings/0001193125-26-218200.md) | [(177.7%)](/filings/0001193125-26-345759.md) | [(10.1%)](/filings/0001193125-25-278837.md) | [(86.5%) d](/filings/0001193125-26-118550.md) | [(111.6%)](/filings/0001193125-26-218200.md) | [(18.7%)](/filings/0001193125-26-345759.md) |
| Net margin | % | [(619.5%)](/filings/0001193125-25-278837.md) | [(759.5%) d](/filings/0001193125-26-118550.md) | [(452.7%)](/filings/0001193125-26-218200.md) | [(196.0%)](/filings/0001193125-26-345759.md) | [(85.4%)](/filings/0001193125-25-278837.md) | [75.7% d](/filings/0001193125-26-118550.md) | [(75.3%)](/filings/0001193125-26-218200.md) | [(34.1%)](/filings/0001193125-26-345759.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001193125-25-278837.md) | not reported | [(2.49)](/filings/0001193125-26-218200.md) | [(2.30)](/filings/0001193125-26-345759.md) | [(0.11)](/filings/0001193125-25-278837.md) | not reported | [(0.58)](/filings/0001193125-26-218200.md) | [(0.33)](/filings/0001193125-26-345759.md) |
| Free cash flow | $m | [(13.7) d](/filings/0001193125-25-278837.md) | [(14.2) d](/filings/0001193125-26-118550.md) | [29.0](/filings/0001193125-26-218200.md) | [(14.9) d](/filings/0001193125-26-345759.md) | [(17.5) d](/filings/0001193125-25-278837.md) | [(2.1) d](/filings/0001193125-26-118550.md) | [(22.9)](/filings/0001193125-26-218200.md) | [(18.8) d](/filings/0001193125-26-345759.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [6.3](/filings/0001193125-26-118550.md) | [43.8](/filings/0001193125-26-118550.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | [(954.9%)](/filings/0001193125-26-118550.md) | [(95.9%)](/filings/0001193125-26-118550.md) |
| Net margin | % | not reported | not reported | not reported | [(918.0%)](/filings/0001193125-26-118550.md) | [(80.1%)](/filings/0001193125-26-118550.md) |
| Diluted EPS | $ per share | [(13.52)](/filings/0001558370-23-002687.md) | [(3.22)](/filings/0001558370-24-004530.md) | [(2.78)](/filings/0001558370-25-002640.md) | [(15.24)](/filings/0001193125-26-118550.md) | [(4.19)](/filings/0001193125-26-118550.md) |
| Free cash flow | $m | [(81.9)](/filings/0001558370-23-002687.md) | [(77.6)](/filings/0001558370-24-004530.md) | [(69.1)](/filings/0001558370-25-002640.md) | [(18.4)](/filings/0001193125-26-118550.md) | [(5.5)](/filings/0001193125-26-118550.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xlo/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $6.4m | 664,021 |  | Unchanged |
| [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $5.7m | 592,300 |  | New +592,300 |
| [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $4.0m | 422,505 |  | Unchanged |
| [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $2.2m | 225,994 |  | Added +161,832 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.7m | 178,517 |  | Added +54,857 |
| [Sio Capital Management, LLC](/funds/1482416.md) | 2026-06-30 | $1.5m | 152,464 |  | Unchanged |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $1.1m | 111,541 |  | New +111,541 |
| [Merck & Co., Inc.](/funds/310158.md) | 2026-06-30 | $1.0m | 105,982 |  | Unchanged |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $614.6k | 64,153 |  | Added +14,587 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $545.6k | 56,954 |  | Reduced −539 |

## Recent filings

[All 342 filings](/companies/xlo/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-12 | 11:40 ET | [10-Q](/filings/0001193125-26-345759.md) | Quarterly report, period 2026-06-30 | 0001193125-26-345759 |
| 2026-08-12 | 11:35 ET | [8-K](/filings/0001193125-26-345753.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-345753 |
| 2026-06-12 | 20:05 ET | [8-K](/filings/0001193125-26-269358.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-269358 |
| 2026-05-12 | 11:40 ET | [10-Q](/filings/0001193125-26-218200.md) | Quarterly report, period 2026-03-31 | 0001193125-26-218200 |
| 2026-05-12 | 11:35 ET | [8-K](/filings/0001193125-26-218194.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-218194 |
| 2026-04-28 | 21:02 ET | [DEF 14A](/filings/0001193125-26-187642.md) | Proxy statement, period 2026-06-10 | 0001193125-26-187642 |
| 2026-04-16 | 11:35 ET | [8-K](/filings/0001193125-26-157940.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-157940 |
| 2026-03-23 | 11:40 ET | [10-K](/filings/0001193125-26-118550.md) | Annual report, period 2025-12-31 | 0001193125-26-118550 |
| 2026-03-23 | 11:33 ET | [8-K](/filings/0001193125-26-118544.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-118544 |
| 2026-03-12 | 12:34 ET | [8-K](/filings/0001193125-26-103150.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-103150 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-118550.md), filed Mar 23, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/45e65b6c-4160-422c-8301-9d758387eaa6)

## About the filer

- CIK: 1840233
- Tickers: XLO
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.